ARTICLE | Clinical News

Bempedoic acid: Ph III CLEAR Outcomes started

January 12, 2017 4:19 PM UTC

Esperion began the double-blind, placebo-controlled, international Phase III CLEAR Outcomes trial to evaluate 180 mg oral bempedoic acid once daily in about 12,600 statin-intolerant patients with hype...

BCIQ Company Profiles

Esperion Therapeutics Inc.

BCIQ Target Profiles

ATP citrate lyase (ACLY)